Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database
Year: 2018
Type: article
Study design: Observational Study
Abstract: Objective: To characterize the initial presentation and clinical course of patients with hepatocyte nuclear factor (HNF) 4A‒ and HNF1B‒MODY in a multinational registry. Design, Setting, and Participants: Within the Diabetes Patienten Verlaufsdokumentation (DPV) registry, 44 patients with HNF4A- and 35 patients with HNF1B-MODY were characterized and compared with patients <20 years old with type 1 diabetes (T1D)/type 2 diabetes (T2D). Main Outcome Measure: Clinical and laboratory parameters, therapy, metabolic control, and extrapancreatic symptoms in patients with HNF1B-MODY. Results: Patients with both MODY types were significantly older than patients with T1D at diagnosis (HNF4A, 13.8 years, and HNF1B, 13.5 years, vs T1D, 8.8 years; P < 0.0001). Mean C-peptide at diagnosis was higher for HNF4A-MODY than for T1D (1.8 vs 0.9 ng/mL; P < 0.01); 36.4% of patients with HNF4A-MODY and 65.7% of patients with HNF1B-MODY were treated with insulin, whereas 20.5% and 8.6% received oral antidiabetics only (P < 0.05 and P < 0.01 vs T2D). At the most recent visit, glycated hemoglobin levels were lower in HNF4A- and HNF1B-MODY (mean, 6.5% and 6.1%) than in T1D (7.9%; P < 0.0001). In 40% of patients with HNF1B-MODY, extrapancreatic symptoms were reported. Several clinical predictors previously described to differentiate between MODY and T1D or T2D were revalidated by logistic regression analyses in this cohort. Conclusion: The DPV registry enabled us to precisely characterize phenotype and treatment in these two rare MODY types. Although phenotype of HNF4A- and HNF1B-MODY showed distinct differences from those of T1D and T2D, 38% of patients were initially misclassified as having T1D or T2D.
Institutions: TUM Klinikum, Technical University of Munich, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Stiftung Charité, Charité – Universitätsmedizin Berlin, Heidelberg University, University of Bonn, Innsbruck Medical University, Universität Ulm, German Center for Diabetes Research
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
Funders: Leona M. and Harry B. Helmsley Charitable Trust, European Federation of Pharmaceutical Industries and Associations, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, European Commission, Bundesministerium für Bildung und Forschung, Universität Ulm, Deutsche Diabetes Gesellschaft, Robert Koch Institut
OpenAlex ID: W2905492527
